Skip to main content
Signal8

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Form S-1 — May 20, 2026

$BCLIForm S-1Filed May 20, 2026, 5:32 PM ET0001104659-26-064628Original filing

Brainstorm Cell Therapeutics Inc. (BCLI) filed an S-1 registration statement to allow selling securityholders to resell up to 7,796,496 shares of common stock, including shares issuable upon exercise of pre-funded warrants and common stock purchase warrants. The company will not receive proceeds from these sales, except for the nominal exercise prices of the warrants, indicating this is a secondary offering driven by existing investors rather than capital raising for operations. The filing reveals significant financial distress, with the independent auditor expressing substantial doubt about the company’s ability to continue as a going concern.

Key figures

Offering Price
0.0005 to 1.45
Shares Offered
7796496
Common Shares
1310528
Last Reported Price
0.716
Common Warrant Shares
4252634
Warrant Exercise Price1
1
Warrant Exercise Price2
1.45
Pre Funded Exercise Price
0.0005
Pre Funded Warrant Shares
2233334

Price after filing

1 day: -1.0%7 days: -3.5%30 days: +20.1%

Close on the filing date to close N calendar days later (from $0.72). Historical, not a forecast.

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.